Unit­ed kills its PhI­II PAH drug af­ter it fails Ty­va­so com­bo study

Just a few weeks af­ter San­doz pushed out a gener­ic ver­sion of Unit­ed Ther­a­peu­tics’ PAH drug Re­mod­ulin, Unit­ed was forced to con­cede an­oth­er set­back for its all-im­por­tant pul­monary ar­te­r­i­al hy­per­ten­sion fran­chise. In a sin­gle sen­tence Unit­ed $UTHR said that its Phase III study of es­uber­aprost com­bined with an­oth­er one of its PAH drugs, Ty­va­so, had failed to beat the brand­ed drug alone.

They dropped the drug. That’s it. Over and out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER